Lactate Dehydrogenase Inhibitor

Antibacterial agent 325 is an antibacterial agent. Antibacterial agent 325 exerts potent broad-spectrum antibacterial activity and shows bactericidal activity. Antibacterial agent induces membrane depolarization, disrupts the membrane integrity, increasess ROS production and lipid peroxidation levels. Antibacterial agent 325 inhibits the metabolic activity and Lactate Dehydrogenase (LDH) activity. Antibacterial agent 325 exhibits low drug resistance development in bacteria, low hemolysis and cytotoxicity. Antibacterial agent 325 can be used for the research of bacterial infection.

Antibacterial agent 306 (Compound 8c), a lactate dehydrogenase inhibitor, is a highly effective antibacterial agent, especially effective against Gram-positive bacteria. Antibacterial agent 306 exhibits MIC against Staphylococcus aureus of as low as 1 μg/mL. Antibacterial agent 306 can not only damage membrane integrity and block the replication of DNA by intercalation, but also make reactive oxygen species (ROS) burst. Antibacterial agent 306 can be used for research on anti-multi-drug resistant bacteria.

(S)-GNE-140 (Standard) is the analytical standard of (S)-GNE-140 (HY-100742B). This product is intended for research and analytical applications. (S)-GNE-140 (Compound 30-S) is the S-enantiomer of GNE-140 (HY-118241). (S)-GNE-140 is an effective lactate dehydrogenase (LDH) inhibitor, with IC₅₀ values of 55 nM for LDHA and 140 nM for LDHB. (S)-GNE-140 can be used in cancer research.

GSK2837808A (Standard) is the analytical standard of GSK2837808A (HY-100681). This product is intended for research and analytical applications. GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.

LDH-IN-1 (Standard) is the analytical standard of LDH-IN-1 (HY-111108). This product is intended for research and analytical applications. LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC₅₀s of 32 and 27 nM for LDHA and LDHB, respectively.

Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1.

Nifurtimox (Standard) is the analytical standard of Nifurtimox. This product is intended for research and analytical applications. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).

Linalyl acetate (Standard) is the analytical standard of Linalyl acetate. This product is intended for research and analytical applications. Linalyl acetate is the principal components of many plant essential oils. Linalyl acetate exhibits anti-anxiety, anti-inflammatory, anti-diabetic, anti-stress, and cardiovascular-regulatory effects. Linalyl acetate is orally active.

GNE-140 racemate (Standard) is the analytical standard of GNE-140 racemate (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is a racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and also a tautomer of GNE-140 (HY-118241). GNE-140 racemate is an orally active lactate dehydrogenase inhibitor, with an IC₅₀ of 3 nM against human LDHA and an IC₅₀ of 5 nM against LDHB. GNE-140 racemate reduces the phosphorylation level and total protein expression of p38 MAPK, and inhibits EGF-induced AKT phosphorylation. GNE-140 racemate decreases lactate production, regulates glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, increases extracellular pH, inhibits cell proliferation, migration and invasion, and induces caspase-3 activation and ROS accumulation. GNE-140 racemate can be used in research related to breast cancer, cystic fibrosis and pancreatic cancer.

Antiparasitic agent-32 (compound M9), a Piperaquine (HY-B1896) analog, is a potent P. falciparum lactate dehydrogenase (Pf LDH)-targeting antiparasitic agent (Pf3D7 IC₅₀ = 0.40 μM). Antiparasitic agent-32 exhibits significant activity against both Pf asexual and gametocyte stages. Antiparasitic agent-32 exerts antiplasmodial activity through stable and specific noncovalent interactions at the NADH-binding site. Antiparasitic agent-32 can be used for malaria research.

Galloflavin potassium is a novel lactate dehydrogenase inhibitor that can be used for the research of cancer. Galloflavin inhibits aerobic glycolysis in PLC/PRF/5 cells and triggers cell death via apoptosis.

FX-11 (Standard) is the analytical standard of FX-11 (HY-16214). This product is intended for research and analytical applications. FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a K_i of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts.

BMS-191095 hydrochloride is a mitochondrial K_ATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects.

Dotarizine is a novel Piperazine (HY-B0912) derivative and antimigraine agent. Dotarizine exhibits Ca²⁺ channel blocking properties. Dotarizine decreases the release of lactate dehydrogenase. Dotarizine shows 5-HT receptor blocking effect.